An investigator gave the World Anti-Doping Agency a pass on its handling of the inflammatory case involving Chinese swimmers, but not without hammering away at the ''curious'' nature of WADA's ''silence'' after examining Chinese actions that did not follow rules designed to safeguard global sports.
WADA on Thursday released the full decision from Eric Cottier, the Swiss investigator it appointed to analyze its handling of the case involving the 23 Chinese swimmers who remained eligible despite testing positive for performance enhancers in 2021.
In echoing wording from an interim report issued earlier this summer, Cottier said it was ''reasonable'' that WADA chose not to appeal the Chinese anti-doping agency's explanation that the positives came from contamination.
''Taking into consideration the particularities of the case, (WADA) appears ... to have acted in accordance with the rules it has itself laid out for anti-doping organizations,'' Cottier wrote.
But peppered throughout his granular, 56-page analysis of the case was evidence and reminders of how WADA disregarded some of China's violations of anti-doping protocols. Cottier concluded this happened more for the sake of expediency than to show favoritism toward the Chinese.
''In retrospect at least, the Agency's silence is curious, in the face of a procedure that does not respect the fundamental rules, and its lack of reaction is surprising,'' Cottier wrote of WADA's lack of fealty to the world anti-doping code.
Travis Tygart, the CEO of the U.S. Anti-Doping Agency and one of WADA's fiercest critics, latched onto this dynamic, saying Cottier's information ''clearly shows that China did not follow the rules, and that WADA management did nothing about it.''
One of the chief complaints over the handling of this case was that neither WADA nor the Chinese gave any public notice upon learning of the positive tests for the banned heart medication Trimetazidine, known as TMZ.